Effect of Glepaglutide, a Long‐Acting Glucagon‐Like Peptide‐2 Analog, on Gastrointestinal Transit Time and Motility in Patients With Short Bowel Syndrome: Findings From a Randomized Trial
- 5 February 2020
- journal article
- research article
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 44 (8) , 1535-1544
Abstract
Background: Patients with short bowel syndrome (SBS) and distal‐bowel resections lack neuroendocrine feedback regulations, potentially resulting in rapid gastrointestinal (GI) transit. The objective was to assess the efficacy of glepaglutide, a long‐acting glucagon‐like peptide‐2 analog, on GI transit in patients with SBS.Methods: In this single‐center, double‐blind, dose‐finding, phase 2 trial, patients with SBS were randomly assigned to 3 treatments (0.1, 1, and 10 mg) in a 2‐period crossover design. Each treatment period included 3 weeks of daily, subcutaneous glepaglutide injections separated by a washout period of 4–8 weeks. Endpoints were changes from baseline and included scintigraphy, wireless motility capsule (WMC, SmartPill Given Imaging, Ltd, Yokneam, Israel), and paracetamol absorption test.Results: A total of 18 patients were randomized. In the 10‐mg dose group (n = 9), glepaglutide significantly increased time to 10% gastric emptying (GE) of solids by 27 (4–50) minutes (adjusted mean [95% CI]), time to 50%GE of fluids by 40 (1–80) minutes, and time to 10% small bowel–emptying of solids by 21 (1–41) minutes. The WMC transit did not significantly change in any of the dose groups. The maximum paracetamol concentration significantly increased in the 10‐mg dose group; however, the area under the curve remained the same.Conclusion: The prolonged GI transit after glepaglutide treatment, along with demonstrated positive effects on intestinal mucosal growth and potential effects on GI hypersecretions, is believed to contribute to the observed beneficial effects on fecal output (primary endpoint) and associated improvement in intestinal absorption.Keywords
Funding Information
- Zealand Pharma
This publication has 22 references indexed in Scilit:
- Regional gastrointestinal transit and pH studied in 215 healthy volunteers using the wireless motility capsule: influence of age, gender, study country and testing protocolAlimentary Pharmacology & Therapeutics, 2015
- The use of SmartPill for gastric monitoringExpert Review of Gastroenterology & Hepatology, 2014
- Scintigraphic assessment of gastrointestinal motility: a brief review of techniques and data interpretationClinical Physiology and Functional Imaging, 2013
- Motility of the antroduodenum in healthy and gastroparetics characterized by wireless motility capsuleNeurogastroenterology & Motility, 2010
- Gastric emptying of a non‐digestible solid: assessment with simultaneous SmartPill pH and pressure capsule, antroduodenal manometry, gastric emptying scintigraphyNeurogastroenterology & Motility, 2008
- Comparison of gastric emptying of a nondigestible capsule to a radio‐labelled meal in healthy and gastroparetic subjectsAlimentary Pharmacology & Therapeutics, 2007
- Inhibition of Sham Feeding-Stimulated Human Gastric Acid Secretion by Glucagon-Like Peptide-2The Journal of Clinical Endocrinology & Metabolism, 1999
- Gastrointestinal hormones in short bowel syndrome. Peptide YY may be the 'colonic brake' to gastric emptying.Gut, 1996
- The relationship between gastric emptying of semisolids and paracetamol absorption.British Journal of Clinical Pharmacology, 1986
- The dependence of paracetamol absorption on the rate of gastric emptyingBritish Journal of Pharmacology, 1973